Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Reports Third Quarter 2024 Financial Results

Tuesday, November 12, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. reported a 12% growth in revenue for the third quarter of 2024. The company reaffirmed its full-year revenue guidance, expecting between $116 million and $120 million, which indicates a growth of 27% to 31%. This positive performance highlights the company's strong market position.
Price reaction · baseline $0.54 (2024-11-12 close) · hit after-hours · clean, no other XTNT news in the window
day 0 close
-13.3%
day 1
-16.9%
day 3 · peak
-20.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Third quarter revenue growth of 12%.
  • Full year revenue guidance reaffirmed at $116M to $120M.
  • Projected growth of 27% to 31% for the year.

Full Press Release Details

Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on

Frequently Asked Questions

What was Xtant Medical's revenue growth in Q3 2024?

Xtant Medical reported a revenue growth of 12% in the third quarter of 2024.

What is the full year revenue guidance for Xtant Medical?

The full year revenue guidance for Xtant Medical is between $116 million and $120 million.

What does the revenue guidance represent in terms of growth?

The revenue guidance represents a growth of 27% to 31% for the year.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical financial results revenue growth 2024 guidance
Last updated: Nov 12, 2024

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk